Search

Genentech Inc., called the 'premier' biotechnology firm by Elise Wang, analyst with Salomon Smith Barney -- and Wang is hardly alone in her opinion -- stands as one of the [...]

The phrase 'rheumatoid arthritis' almost right away calls to mind Genentech Inc.'s Rituxan (rituximab, which targets the CD20 antigen, for RA and non-Hodgkin's lymphoma). Partnered for marketing with Biogen Idec [...]

Recalling biotechnology battles is almost like re-living boxing matches from the past. Who could forget when Genzyme Corp. faced off against Transkaryotic Therapies Inc. to get first approval for a [...]

The perhaps unreasonable power of preliminary data--especially when it's offered by an industry powerhouse--was proved once again late last month when mighty Genentech Inc. disclosed positive early figures from a [...]

'Happy new year' might not be the way, exactly, to describe the sort of 2005 that oncologists--not to mention their patients--might expect as a result of changes wrought by the [...]

Tarceva, the eye-opening cancer drug with a new drug application pending, typically is regarded as another feather in the cap of Genentech Inc., whose headgear already is festooned with plumage. [...]

It wasn't exactly a 'shot heard 'round the world,' but Genentech Inc.'s balking earlier this month at paying full royalties to Protein Design Labs Inc. on the asthma drug Xolair [...]

Gone are the days when a dollop of good news in any area of biotechnology lit a fire under stocks across the sector. Investors, having become at least somewhat more [...]

Nuts. Last month, when the FDA approved Xolair for asthma, there was much rejoicing by Genentech Inc., Tanox Inc. and Novartis Pharma AG, which developed the monoclonal antibody in a [...]

CHICAGO--'You name the diseases in medicine that we cure,' said David Cunningham, lead investigator in Merck KGgA's clinical trial with Erbitux (cetuximab), which became one of the stars at this [...]

Among the headliners at the upcoming meeting of the American Society of Clinical Oncology are details on the eye-opening success of Genentech Inc.'s vascular endothelial growth factor drug Avastin (bevacizumab) [...]

With the dropping of the Avastin (bevacizumab) shoe last week--Genentech Inc. disclosed Phase III data showing the breast cancer drug missed its primary efficacy endpoint--came a renewed focus not only [...]

The climate may cool with September's advent, but the industry late last week was still expecting a blast of potentially hot autumnal news about Phase III trials of Genentech Inc.'s [...]

NEW YORK -- The curiosity of new investors and an apparent financial upswing (heralded partly by the opening squeak of an initial public offerings window) gained credit for drawing a [...]

'Robust' is defined by Webster's as 'strong and healthy; hardy; vigorous.' It's a word used as often to describe Iowa farmhands, flour-dusted lady bakers, and Colombian coffees, as it is [...]

Like notches in a belt, patents for biotech firms seem to certify strength and credibility, as well as portend a solid future for the companies that hold them. The more [...]

'War! What is it good for? Absolutely nothin',' boomed an over-the-top hippie anthem from the late 1960s. But in biotechnology, battles over intellectual property--drawn out and costly as they may [...]

SAN FRANCISCO -- Industry leader and self-made man Roy Vagelos, former chairman and CEO of Merck & Co. Inc., offered words of wisdom about keeping talent in the coming half-century, [...]

'Short people got no reason to live,' Randy Newman sang in a satirical, widely misunderstood 1977 tune about discrimination against the height-challenged. As an endocrine disorder, failure to grow is [...]

The near-term meaning of this month's blowup of AstraZeneca plc's Iressa, the epidermal growth factor inhibitor against non-small-cell lung cancer, was clear--a strong boost for Genentech Inc. and OSI Pharmaceuticals [...]

As everybody in the biotechnology 'hood knows, big dogs can fight longer than smaller dogs--and Genentech Inc.'s legal scrap with Amgen Inc. over the way Amgen makes the blockbusters Neupogen [...]

Investors are likely to be all ears this week when Genentech Inc. hosts its annual meeting with stockholders. A recent earnings report and other news from the pioneering company -- [...]